News

5 call topics for 2024 will be cancelled or postponed

Published on | 2 years ago

Programmes
Digital, Industry & Space

If you are working on a proposal for one of the call topics from the list below, you'd better hold you horses, because these call topics will get cancelled or postponed. The reason behind this drastic action is a huge Work Plan update that aims at putting Europe on the global map again in the field of AI (e.g. LLM), or to broaden the scope (e.g. both 2-dimensional and advanced materials).

Affected call topics

Call HORIZON-CL4-2024-HUMAN-01

The Commission intends to cancel 3 topics included in this call (a human-centred and ethical development of digital and industrial technologies) will get cancelled.

  • HORIZON-CL4-2024-HUMAN-01-06: Explainable and Robust AI (RIA), EUR 30.00 million
  • HORIZON-CL4-2024-HUMAN-01-07: Collaborative intelligence – combining the best of machine and human (RIA), EUR 20.00 million
  • HORIZON-CL4-2024-HUMAN-01-61: Facilitate the engagement in global ICT standardisation development (CSA), EUR 6.00 million

The first two call topics will be replaced by a new call for projects that would better support the policy needs emerging from the fast evolving trend on Artificial Intelligence, in particular around generative Artificial Intelligence. This strategy also aims to secure sovereignty over AI technology, requiring projects with sufficient critical mass.The third call topic one will most likely just be postponed and added (unchanged) to the later call, that would open in April 2024. 

Call HORIZON-CL4-2024-DIGITAL-EMERGING-01-CNECT

The Commission intends to cancel 2 topics included in this call (Digital and emerging technologies for competitiveness and fit for the Green Deal)..

  • HORIZON-CL4-2024-DIGITAL-EMERGING-01-34: Synergy with national and regional initiatives in Europe (CSA), EUR 3.00 million.
  • HORIZON-CL4-2024-DIGITAL-EMERGING-01-42: Stimulating transnational research and development of next generation quantum technologies, including basic theories and components (RIA), EUR 15.00 million.

For the first call topic, the Commission is considering a new topic in a new call with a broader scope that would support the coordination of national and regional initiatives for both two-dimensional and advanced materials. The latter topic is most likely to be postponed and will be added (unchanged) to the new call for a better coordination with the national funding agencies, that would open in April 2024.

When will there be clarity?

There will be an unclear situation until the beginning of 2024

The new call will only be published when an amendment to the Work Programme has been adopted by the European Commission. This is expected to happen in early Feb 2024. Only the adopted work programme will have legal value. The adoption of the amended WP will be announced on the F&T Portal. The Commission expressly disclaims liability for any future changes of the content of this call/topic.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1833 articles available search in articles 

Testimonial

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.